{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:27:50Z","timestamp":1786123670080,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clgc.2026.102624","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:20:32Z","timestamp":1783700432000},"page":"102624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Prognostic Role of HER2 Expression in Patients With Non\u2013Muscle-Invasive Bladder Cancer"],"prefix":"10.1016","volume":"24","author":[{"given":"Xuejian","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingkai","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengye","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashi","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clgc.2026.102624_bib0001","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ)-a summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102624_bib0002","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.eururo.2013.04.027","volume":"64","author":"Inman","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102624_bib0003","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0022-5347(17)51695-X","article-title":"Superficial bladder cancer: progression and recurrence","volume":"130","author":"Heney","year":"1983","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102624_bib0004","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with Bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102624_bib0005","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.clgc.2026.102624_bib0006","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cam4.3007","article-title":"Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): a cohort analysis","volume":"9","author":"Jobczyk","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.clgc.2026.102624_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1424293","article-title":"Deciphering the molecular heterogeneity of intermediate- and (very-)high-risk non-muscle-invasive bladder cancer using multi-layered -omics studies","volume":"14","author":"Akand","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2026.102624_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104862","article-title":"Emerging biomarkers in bladder cancer: translating molecular advances into precision oncology","volume":"215","author":"Ferro","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102624_bib0009","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-023-00608-0","article-title":"Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Delta16HER2-driven breast cancer initiation in mice","volume":"10","author":"Favero","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clgc.2026.102624_bib0010","article-title":"HER2 and urothelial carcinoma: current understanding and future directions","author":"Raggi","year":"2025","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102624_bib0011","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12575-025-00261-w","article-title":"Impact of HER2 expression on the prognosis of muscle-invasive bladder cancer patients treated with bladder-preservation comprehensive therapy","volume":"27","author":"Chen","year":"2025","journal-title":"Biol Proced Online"},{"issue":"4","key":"10.1016\/j.clgc.2026.102624_bib0012","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.euo.2023.10.003","article-title":"Prognostic significance of HER2 expression in patients with Bacillus Calmette-Guerin-exposed non-muscle-invasive bladder cancer","volume":"7","author":"Tan","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102624_bib0013","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/JS9.0000000000000859","article-title":"HER2 overexpression predicts pathological T2 stage and improved survival in de novo muscle-invasive bladder cancer after immediate radical cystectomy: a retrospective cohort study","volume":"110","author":"Kim","year":"2024","journal-title":"Int J Surg"},{"issue":"7","key":"10.1016\/j.clgc.2026.102624_bib0014","article-title":"Intravesical disitamab Vedotin (RC48) for HER2-expressing high-risk non-muscle-invasive bladder cancer: a single-arm, dose-escalation phase I trial study","volume":"6","author":"Chen","year":"2025","journal-title":"MedComm (2020)"},{"issue":"32","key":"10.1016\/j.clgc.2026.102624_bib0015","article-title":"A HER2-targeted antibody-drug conjugate, RC48-ADC, exerted promising antitumor efficacy and safety with intravesical instillation in preclinical models of bladder cancer","volume":"10","author":"Hong","year":"2023","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"10.1016\/j.clgc.2026.102624_bib0016","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102624_bib0017","first-page":"1001","article-title":"Clinical pathological expert consensus on HER-2 testing in urothelial carcinoma in China","volume":"43","year":"2021","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"6","key":"10.1016\/j.clgc.2026.102624_bib0018","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1002\/jmri.29342","article-title":"MRI-based machine learning radiomics for preoperative assessment of human epidermal growth factor receptor 2 status in urothelial bladder carcinoma","volume":"60","author":"Yu","year":"2024","journal-title":"J Magn Reson Imaging"},{"issue":"2","key":"10.1016\/j.clgc.2026.102624_bib0019","first-page":"121","article-title":"Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer","volume":"3","author":"Lei","year":"2023","journal-title":"J Natl Cancer Cent"},{"issue":"5","key":"10.1016\/j.clgc.2026.102624_bib0020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/14737140.2017.1313119","article-title":"Tackling non-muscle invasive bladder cancer in the clinic","volume":"17","author":"Woldu","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10061","key":"10.1016\/j.clgc.2026.102624_bib0021","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clgc.2026.102624_bib0022","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/S0022-5347(01)67321-X","article-title":"The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years","volume":"153","author":"Holm\u00e4ng","year":"1995","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102624_bib0023","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2023.7086","article-title":"Outcomes of a dietary intervention to reduce bladder cancer recurrence and progression in survivors of non-muscle-invasive bladder cancer","volume":"22","author":"Yeary","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.clgc.2026.102624_bib0024","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/bju.16828","article-title":"Enhanced prognostic value of four-tier hybrid grading system in Ta non-muscle-invasive bladder cancer","volume":"136","author":"Ferro","year":"2025","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.clgc.2026.102624_bib0025","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.urology.2003.10.040","article-title":"HER-2\/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder","volume":"63","author":"Coogan","year":"2004","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.clgc.2026.102624_bib0026","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.clgc.2026.102624_bib0027","article-title":"HER2-CD3-Fc bispecific antibody-encoding mRNA delivered by lipid nanoparticles suppresses HER2-positive tumor growth","volume":"12","author":"Hu","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.clgc.2026.102624_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103997","article-title":"A review of HER2 overexpression and somatic mutations in cancers","volume":"186","author":"Galogre","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102624_bib0029","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1186\/s12967-023-04528-2","article-title":"Preoperative fluorescence in situ hybridization analysis as a predictor of tumor recurrence in patients with non-muscle invasive bladder cancer: a bi-institutional study","volume":"21","author":"Zheng","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.clgc.2026.102624_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-025-01211-1","article-title":"Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: a multicenter real-world study","author":"Guo","year":"2025","journal-title":"NPJ Precis Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102624_bib0031","doi-asserted-by":"crossref","DOI":"10.1002\/imt2.70033","article-title":"Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC) combined immunotherapy in patients with muscle-invasive bladder cancer: a multi-center real-world study","volume":"4","author":"Hu","year":"2025","journal-title":"Imeta"},{"key":"10.1016\/j.clgc.2026.102624_bib0032","article-title":"Efficacy and safety of Disitamab Vedotin combined with Gemcitabine as neoadjuvant therapy in muscle-invasive bladder cancer: an open-label, multicenter, single-arm, phase 2 trial","author":"Huang","year":"2025","journal-title":"Eur Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:26Z","timestamp":1786119326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1558767326001242"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102624","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Prognostic Role of HER2 Expression in Patients With Non\u2013Muscle-Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102624","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102624"}}